Bergen, Norway, 10 November 2017 - BerGenBio ASA, a clinical-stage
biopharmaceutical company developing novel, selective Axl kinase inhibitors for
multiple cancer indications, will announce its results for the third quarter
2017 on Friday, 17 November 2017.
A presentation by BerGenBio's senior management team will take place at 9.00 am
CET at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: Bjørvika

The presentation will webcast live and the link will be available at
www.bergenbio.com in the section Investors/Reports and presentations/Webcasts. A
recording will be available shortly after the webcast has finished.

The results report and the presentation will be available at www.bergenbio.com
in the section: Investors/Reports and presentations from 7:00 am CET the same
day.

-Ends-